Trial Profile
A PHASE 1 OPEN-LABEL PHARMACOKINETICS STUDY OF PALBOCICLIB, A CYCLIN-DEPENDENT KINASE 4 AND 6 (CDK4/6) INHIBITOR, IN POSTMENOPAUSAL CHINESE WOMEN WITH ER (+), HER2 (-) ADVANCED BREAST CANCER
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Letrozole
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 23 Jun 2022 Planned End Date changed from 26 Jan 2020 to 30 Jan 2023.
- 23 Sep 2021 Data from this study was to used to develop PKPD models for 3 biomarkers that related to CDK4/6 modulation were published in the Journal of Clinical Pharmacology
- 05 Aug 2018 Planned End Date changed from 1 Jan 2020 to 26 Jan 2020.